Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study.
Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi NM. Casale P, et al. Among authors: lughezzani g. Minerva Urol Nefrol. 2019 Jun;71(3):273-279. doi: 10.23736/S0393-2249.19.03279-X. Epub 2019 Jan 28. Minerva Urol Nefrol. 2019. PMID: 30700081 Free article.
Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS.
Hurle R, Lazzeri M, Saita A, Naselli A, Guarneri A, Buffi NM, Lughezzani G, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Peschechera R, Benetti A, Zandegiacomo S, Lista G, Pasini L, Guazzoni G, Casale P. Hurle R, et al. Among authors: lughezzani g. Minerva Urol Nefrol. 2019 Aug;71(4):406-412. doi: 10.23736/S0393-2249.19.03254-5. Epub 2019 May 28. Minerva Urol Nefrol. 2019. PMID: 31144485 Free article.
Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
Hurle R, Casale P, Saita A, Colombo P, Elefante GM, Lughezzani G, Fasulo V, Paciotti M, Domanico L, Bevilacqua G, Maffei D, Diana P, Frego N, Sandri MT, Maura F, Morenghi E, Buffi NM, Guazzoni G, Lazzeri M. Hurle R, et al. Among authors: lughezzani g. World J Urol. 2020 Sep;38(9):2215-2220. doi: 10.1007/s00345-019-03002-3. Epub 2019 Nov 5. World J Urol. 2020. PMID: 31691083
Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis.
Klotz L, Lughezzani G, Maffei D, Sánchez A, Pereira JG, Staerman F, Cash H, Luger F, Lopez L, Sanchez-Salas R, Abouassaly R, Shore ND, Eure G, Paciotti M, Astobieta A, Wiemer L, Hofbauer S, Heckmann R, Gusenleitner A, Kaar J, Mayr C, Loidl W, Rouffilange J, Gaston R, Cathelineau X, Klein E. Klotz L, et al. Among authors: lughezzani g. Can Urol Assoc J. 2021 Jan;15(1):E11-E16. doi: 10.5489/cuaj.6712. Can Urol Assoc J. 2021. PMID: 32701437 Free PMC article.
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R, Contieri R, Casale P, Morenghi E, Saita A, Buffi N, Lughezzani G, Colombo P, Frego N, Fasulo V, Paciotti M, Guazzoni G, Lazzeri M. Hurle R, et al. Among authors: lughezzani g. Urol Oncol. 2021 Mar;39(3):195.e7-195.e13. doi: 10.1016/j.urolonc.2020.09.017. Epub 2020 Oct 23. Urol Oncol. 2021. PMID: 33268275
234 results